Adocia

Adocia’s BioChaperone platform transforms diabetes care with ultra‑rapid insulin, glucagon and GLP‑1 combos, offering faster action, better control and new metabolic therapies.

Discover how Adocia’s BioChaperone platform is redefining diabetes and metabolic disease treatment, with ultra‑rapid insulin and GLP‑1 combos boosting safety and efficacy.

Adocia SA, a clinical-stage biotechnology company, is making significant strides in the healthcare sector with its proprietary BioChaperone technology and diverse product pipeline, positioning it for a promising future in the treatment of diabetes a…